Direct-acting oral anticoagulants (DOACs): bleeding risk and reversal agents
Posted 10 Sept 2020
Dr Julie Oliver
Dr Julie Oliver discusses this topic in the context of a recent update from the Medicines and Healthcare products Regulatory Agency (MHRA).
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page